The ADR is currently trading at $11.90, down $0.67 from the previous close. The company’s quarterly performance was impacted by provisions related to the semaglutide ingredients issue and a decline in generics revenue in North America.
The ADR is currently trading at $11.90, down $0.67 from the previous close. The company’s quarterly performance was impacted by provisions related to the semaglutide ingredients issue and a decline in generics revenue in North America.